In the absence of evidence of benefit for acute low back pain, its over‐the‐counter availability should be reconsidered
Decades of opioid overuse can teach us valuable lessons about how we should handle medicinal cannabinoids, including cannabidiol (CBD). One major lesson is that access to medicines should not move ahead of scientific evidence. Over time, evidence that context is critical has accumulated: using opioids to treat acute pain and cancer pain, in the management of opioid dependency, and in palliative care can be justified. However, the indication creep from acute to chronic non‐cancer pain was unwarranted. Consequently, clinicians are sensitive to new pain medicines being made available without evidence of benefit, and the motivations for accelerated access have been questioned.1
- 1. Bell RF, Kalso EA. Cannabinoids for pain or profit? Pain 2020; https://doi.org/10.1097/j.pain.0000000000001930 [online ahead of print].
- 2. Therapeutic Goods Administration. Medicinal cannabis: role of the TGA [website]. Mar 2021. https://www.tga.gov.au/medicinal-cannabis-role-tga (viewed Mar 2021).
- 3. Fisher E, Moore RA, Fogarty AEW, et al. Cannabinoids, cannabis, and cannabis‐based medicines for pain management. Pain 2020; https://doi.org/10.1097/j.pain.0000000000001929 [online ahead of print].
- 4. Stockings E, Campbell G, Hall W, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta‐analysis of controlled and observational studies. Pain 2018; 159: 1932–1954.
- 5. McCartney D, Benson MJ, Desbrow B, et al. Cannabidiol and sports performance: a narrative review of relevant evidence and recommendations for future research. Sports Med Open 2020; 6: 27.
- 6. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta‐analysis of randomized clinical trials. Neuropsychopharmacol 2020; 45: 1799–1806.
- 7. Huestis MA, Solimini R, Pichini S, et al. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol 2019; 17: 974–989.
- 8. Senate Standing Committees on Community Affairs. Current barriers to patient access to medicinal cannabis in Australia. https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Medicinalcannabis (viewed Mar 2021).
- 9. Therapeutic Goods Administration. Proposed amendments to the Poisons Standard: joint ACMS/ACCS meetings, June 2020. Apr 2020. https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-joint-acmsaccs-meetings-june-2020 (viewed Mar 2021).
- 10. Therapeutic Goods Administration. Over-the‐counter access to low dose cannabidiol [media release]. 15 Dec 2020. https://www.tga.gov.au/media-release/over-counter-access-low-dose-cannabidiol (viewed Mar 2021).
- 11. Millar SA, Stone NL, Bellman ZD, et al. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2019; 85: 1888–1900.
- 12. Kocis PT, Vrana KE. Delta‐9-tetrahydrocannabinol and cannabidiol drug–drug interactions. Med Cannabis Cannabinoids 2020; 3: 61–73.
- 13. Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust 2021; 214: 370–375.
- 14. Manini AF, Yiannoulos G, Bergamaschi MM, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med 2015; 9: 204–210.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.